These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25517472)

  • 1. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
    Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
    AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
    J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Renaud-Théry F; Shaffer N; Hargreaves S; Mills EJ; Ford N
    AIDS; 2013 Jun; 27(9):1403-12. PubMed ID: 23343913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S; Evans D; Zuma K; Okello V; Louwagie G
    Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
    van den Berg-Wolf M; Hullsiek KH; Peng G; Kozal MJ; Novak RM; Chen L; Crane LR; Macarthur RD;
    HIV Clin Trials; 2008; 9(5):324-36. PubMed ID: 18977721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
    Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
    Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
    AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
    BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
    Knobel H; Guelar A; Montero M; Carmona A; Luque S; Berenguer N; González A
    HIV Med; 2008 Jan; 9(1):14-8. PubMed ID: 18199168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.